Oral contraceptives to prevent pregnancy and diminish...

Details Oral contraceptives to prevent pregnancy and diminish... Oral contraceptives to prevent pregnancy and diminish...

2008-01-22

2008-01-22

Hui, San-Ming (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S171000, C514S182000

Reexamination Certificate

active

07320969

ABSTRACT:
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.

REFERENCES:
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4215691 (1980-08-01), Wong
patent: 4291014 (1981-09-01), Keith et al.
patent: 4292315 (1981-09-01), Vorys
patent: 4438139 (1984-03-01), Keith et al.
patent: 4685911 (1987-08-01), Konno et al.
patent: 4752478 (1988-06-01), Bondi et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4962098 (1990-10-01), Boissonneault
patent: 4971998 (1990-11-01), Wurtman et al.
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5256421 (1993-10-01), Casper
patent: 5276022 (1994-01-01), Casper
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5382573 (1995-01-01), Casper
patent: 5510341 (1996-04-01), Ehrlich et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5567695 (1996-10-01), Labrie
patent: 5585370 (1996-12-01), Casper
patent: 5633242 (1997-05-01), Oettel et al.
patent: 5662927 (1997-09-01), Ehrlich et al.
patent: RE35724 (1998-02-01), Pasquale
patent: 5747480 (1998-05-01), Gast
patent: 5753639 (1998-05-01), Labrie
patent: 5756490 (1998-05-01), Lachnit et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 5858405 (1999-01-01), Gast
patent: 5898032 (1999-04-01), Hodgen
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5980940 (1999-11-01), Spona et al.
patent: 6028064 (2000-02-01), Rodriguez et al.
patent: 6251956 (2001-06-01), Kafrissen et al.
patent: 6265393 (2001-07-01), Heinrichs
patent: 6306914 (2001-10-01), de Ziegler et al.
patent: 6312722 (2001-11-01), Schmidt-Gollwitzer et al.
patent: 6319911 (2001-11-01), Rodriguez
patent: RE37838 (2002-09-01), Spona et al.
patent: 6451779 (2002-09-01), Hesch
patent: 6500814 (2002-12-01), Hesch
patent: 6511970 (2003-01-01), Rodriguez
patent: 6787531 (2004-09-01), Hilman et al.
patent: 2001/0044431 (2001-11-01), Rodriguez
patent: 2002/0132801 (2002-09-01), Heil et al.
patent: 2003/0018018 (2003-01-01), Hodgen et al.
patent: 2003/0114429 (2003-06-01), Hilman et al.
patent: 2003/0119798 (2003-06-01), Heil et al.
patent: 2003/0144258 (2003-07-01), Heil et al.
patent: 2003/0216366 (2003-11-01), Leonard et al.
patent: 2003/0229057 (2003-12-01), Caubel et al.
patent: 2004/0009960 (2004-01-01), Heil et al.
patent: 2004/0142914 (2004-07-01), Friedman et al.
patent: 2006/0135496 (2006-06-01), DiLiberti et al.
patent: 0 253 607 (1988-01-01), None
patent: 0 911 029 (2002-04-01), None
patent: WO93/17686 (1993-09-01), None
patent: WO 98/04246 (1998-02-01), None
patent: WO 98/04266 (1998-02-01), None
patent: WO 98/04267 (1998-02-01), None
patent: WO 00/38691 (2000-07-01), None
patent: WO 02/03975 (2002-01-01), None
patent: WO 2004/080442 (2004-09-01), None
patent: WO 2005/032558 (2005-04-01), None
Katzung, Basic & Clinical Pharmacology, 6th ed., 1995, p. 619-623.
Merck Index, 11th ed., 1989, monograph 4112.
American Psychiatric Association, “Premenstrual Dysphoric Disorder,” inDSM-IV™: Diagnostic and Statistical Manual of Mental Disorders, 4thedition, American Psychiatric Association, Washington, DC, pp. 715-718 (1994).
Cachrimanidou, A.-C., et al., “Long-interval treatment regimen with a desogestrel-containing oral contraceptive,”Contraception 48:205-216, Butterworth-Heinemann (1993).
de Voogd, W.S., “Postponement of Withdrawal Bleeding With a Monophasic Oral Contraceptive Containing Desogestrel and Ethinylestradiol,”Contraception 44:107-112, Butterworth-Heinemann (1991).
Frackiewicz, E.J., and Shiovitz, T.M., “Evaluation and Management of Premenstrual Syndrome and Premenstrual Dysphoric Disorder,”J. Am. Pharm. Assoc. 41:437-447, American Pharmaceutical Association (May/Jun. 2001).
Hamerlynck, J.V.Th.H., et al., “Postponement of Withdrawal Bleeding in Women Using Low-Dose Combined Oral Contraceptives,”Contraception 35:199-205, Geron-X, Inc. (1987).
Hipkin, L.J., “The Induction of Amenorrhoea,”J. R. Army Med. Corps 138:15-18, London Royal Army Medical Corps (1992).
Kornaat, H., et al., “The Acceptance of a 7-Week Cycle With a Modern Low-Dose Oral Contraceptive (Minulet•),”Contraception 45:119-127, Butterworth-Heinemann (1992).
Kovacs, G.T., et al., “A trimonthly regimen for oral contraceptives,”Br. J. Fam. Plann. 19:274-275, Faculty of Family Planning and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists (1994).
Loudon, N.B., et al., “Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen,”Br. Med. J. 2:487-490, British Medical Association (1977).
Mortola, J.F., et al., “Diagnosis of Premenstrual Syndrome by a Simple, Prospective, and Reliable Instrument: The Calendar of Premenstrual Experiences,”Obstet. Gynecol. 76:302-307, Elsevier Science Publishing Co., Inc. (1990).
Romano, S., et al., “The Role of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder,”Clin. Ther. 21:615-633, Excerpta Medica, Inc. (1999).
Sheth, A., et al., “A Randomized, Double-Blind Study of Two Combined and Two Progestogen-Only Oral Contraceptives,”Contraception 25:243-252, Geron-X, Inc. (1982).
Silberstein, S.D., and Merriam, G.R., “Physiology of the menstrual cycle,”Cephalalgia 20:148-154, Blackwell Science Ltd. (Apr. 2000).
Stearns, S., “PMS and PMDD in the Domain of Mental Health Nursing,”J. Pyschosoc. Nurs. 39:16-27, Slack Incorporated (Jan. 2001).
Steiner, M., et al., “Fluoxetine in the Treatment of Premenstrual Dysphoria,”N. Engl. J. Med. 332:1529-1534, Massachusetts Medical Society (1995).
Steiner, M., “Premenstrual Syndromes,”Annu. Rev. Med. 48:447-455, Annual Reviews Inc. (1997).
Steiner, M., and Born, L., “Diagnosis and treatment of premenstrual dysphoric disorder: an update,”Int. Clin. Psychopharmacol. 15(Suppl. 3):S5-S17, Lippincott Williams & Wilkins (Nov. 2000).
Sulak, P.J., et al., “Extending the Duraction of Active Oral Contraceptive Pills to Manage Hormone Withdrawal Symptoms,”Obstet. Gynecol. 89:179-183, Elsevier Science Inc. (1997).
Yonkers, K.A., “Antidepressants in the Treatment of Premenstrual Dysphoric Disorder,”J. Clin. Psychiatry 58(Suppl. 14):4-13, Physicians Postgraduate Press (1997).
Yonkers, K.A., “Medical Management of Premenstrual Dysphoric Disorder,”J. Gend. Specif. Med. 2:55-60, Multimedia Healthcare (1999).
Daugherty, J.E., “Treatment Strategies for Premenstrual Syndrome,”Am. Family Physician 58:183-192 and 2 page insert, American Academy of Family Physicians (1998).
Freeman, E.W., et al., “Concurrent Use of Oral Contraceptives With Antidepressants for Premenstrual Syndromes,”J. Clin. Pschyopharmacol. 21:540-542, Lippincott Williams & Wilkins (Oct. 2001).
Küpper, C., and Loch, E.-G., “Prämenstruelles Syndrom,”Deutsche Apotheker Zeitung 136:23-29, Deutcher Apotheker Verlag (1996).
Dickey, R.P., “Oral Contraception: Realizing the Promise by Overcoming the Pitfalls,”Individualizing Oral Contraceptive Therapy, OBG Management Supplement, pp. 2-6, Watson Pharma, Inc. (Oct. 2000).
European Opposition Document, Notice of Opposition (Article 99 and Rule 55 EPC), submitted by Akzo Nobel N.V. in the Opposition to European Patent No. 0 911 029 B1, 8 pages (Jan. 2002).
European Opposition Document, Notice and Statement of Opposition, submitted by Shering AG in the Oppositon to European Patent No. 0 911 029 B1, 32 pages (Jan. 2003).
European Opposition Document, Response to Communication of Notices of Opposition, submitted by Patentee in the Opposition to European Patent No. 0 911 029 B1, 10 pages (

Affiliated with

Also associated with

Rating

Oral contraceptives to prevent pregnancy and diminish... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral contraceptives to prevent pregnancy and diminish..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral contraceptives to prevent pregnancy and diminish... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2790425